Marc Goodman

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened:  Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...

Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday. What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company. Since its launch in March...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

Biogen Inc (NASDAQ: BIIB) shares are retreating sharply after an Adcom committee recommended against approval of its investigational Alzheimer's drug aducanumab. Despite the setback, an analyst at SVB Leerink said aducanumab could still successfully clear the final FDA hurdle. The Biogen...

Biogen Inc (NASDAQ: BIIB) reported fairly solid third-quarter results Wednesday, sending its shares higher.  Against this backdrop, an analyst at SVB Leerink said the key to outperformance for the company is a positive regulatory ruling on its controversial Alzheimer's treatment candidate...

Shares of small-cap biopharma Marinus Pharmaceuticals Inc (NASDAQ: MRNS) were moving sharply higher to a new 52-week high Tuesday following the release of positive results for ganaxolone, the only investigational asset in its pipeline. What Happened: Randor, Pennsylvania-based Marinus said its...

Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day. What Happened: The FDA accepted the aducanumab biologics license application for priority...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

With concerns about Acthar, which fetches Mallinckrodt PLC (NYSE: MNK) roughly one-third of its revenues, UBS tempered its expectations. The Analyst & Rating UBS analyst Marc Goodman downgraded shares of Mallinckrodt from Buy to Neutral and lowered its 12-month price target from $70 to $24, a...

The earnings season is picking up momentum next week, with several widely followed and high-profile companies lined up to release their quarterly results. Here is a brief on companies due to report and what to expect from each. 1. General Motors Date of reporting: Oct. 24. Consensus: EPS: $1...

UBS downgraded shares of AbbVie Inc (NYSE: ABBV), citing valuation and a likely delay in the U.S. biosimilar competition for Humira. Humira is AbbVie's best-selling drug approved to treat multiple indications such as rheumatoid arthritis, psoriatic arthritis and Crohn's disease, among others....

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) said Tuesday it has agreed to sell its Paragard IUD product to Cooper Companies Inc (NYSE: COO) in a $1.1 billion cash deal. Teva also confirmed it will continue divesting the remaining assets it holds within the women's health portfolio along...

Five analysts have downgraded Teva Pharmaceuticals Industries Ltd (ADR) (NYSE: TEVA) since it reported its second-quarter earnings on Thursday before the market opened. Credit Suisse’s Vamil Diva is one of them, moving from Outperform to Neutral with a price target dropped from $39 to $25....

UBS keyed into expectations for some of next week’s highest profile earnings reports, providing updated insights for their high-conviction trading ideas. Among the names were Apple Inc. (NASDAQ: AAPL), Pfizer Inc. (NYSE: PFE), Tesla Inc (NASDAQ: TSLA) and Activision Blizzard, Inc. (NASDAQ:...